JP2011503065A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503065A5
JP2011503065A5 JP2010533100A JP2010533100A JP2011503065A5 JP 2011503065 A5 JP2011503065 A5 JP 2011503065A5 JP 2010533100 A JP2010533100 A JP 2010533100A JP 2010533100 A JP2010533100 A JP 2010533100A JP 2011503065 A5 JP2011503065 A5 JP 2011503065A5
Authority
JP
Japan
Prior art keywords
beta
alpha
integrin inhibitor
proteinuria
αvβ3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010533100A
Other languages
English (en)
Japanese (ja)
Other versions
JP5637855B2 (ja
JP2011503065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/012541 external-priority patent/WO2009061448A2/en
Publication of JP2011503065A publication Critical patent/JP2011503065A/ja
Publication of JP2011503065A5 publication Critical patent/JP2011503065A5/ja
Application granted granted Critical
Publication of JP5637855B2 publication Critical patent/JP5637855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010533100A 2007-11-08 2008-11-07 蛋白尿症の治療のための方法及び組成物 Expired - Fee Related JP5637855B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US244507P 2007-11-08 2007-11-08
US61/002,445 2007-11-08
PCT/US2008/012541 WO2009061448A2 (en) 2007-11-08 2008-11-07 Methods and compositions for the treatment of proteinuric diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014120429A Division JP2014205690A (ja) 2007-11-08 2014-06-11 蛋白尿症の治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2011503065A JP2011503065A (ja) 2011-01-27
JP2011503065A5 true JP2011503065A5 (https=) 2011-12-22
JP5637855B2 JP5637855B2 (ja) 2014-12-10

Family

ID=40626390

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010533100A Expired - Fee Related JP5637855B2 (ja) 2007-11-08 2008-11-07 蛋白尿症の治療のための方法及び組成物
JP2014120429A Pending JP2014205690A (ja) 2007-11-08 2014-06-11 蛋白尿症の治療のための医薬組成物
JP2015247171A Pending JP2016104767A (ja) 2007-11-08 2015-12-18 蛋白尿症の治療のための方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014120429A Pending JP2014205690A (ja) 2007-11-08 2014-06-11 蛋白尿症の治療のための医薬組成物
JP2015247171A Pending JP2016104767A (ja) 2007-11-08 2015-12-18 蛋白尿症の治療のための方法及び組成物

Country Status (5)

Country Link
US (3) US9345739B2 (https=)
EP (2) EP2730282A1 (https=)
JP (3) JP5637855B2 (https=)
ES (1) ES2457822T3 (https=)
WO (1) WO2009061448A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2457822T3 (es) * 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
CA2779958A1 (en) * 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
DE102009000854A1 (de) * 2009-02-13 2010-08-19 Ernst-Moritz-Arndt-Universität Greifswald Osteopontin-Rezeptor-Liganden zur Behandlung des chronischen Nierenversagens
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
JP6055464B2 (ja) 2011-05-09 2016-12-27 ザ ユニバーシティー オブ マイアミ 循環血中の可溶性ウロキナーゼ受容体の低減
CN104768975A (zh) 2012-08-31 2015-07-08 北卡罗来纳大学教堂山分校 用于增强或抑制胰岛素-样生长因子1(igf-1)的单克隆抗体
US20180284131A1 (en) * 2015-09-25 2018-10-04 The General Hospital Corporation Diagnostic assays for supar-β3 integrin driven kidney diseases
BR112018012981A2 (pt) 2015-12-30 2018-12-04 Saint Louis University derivados do ácido meta-azacíclico amino benzoico como antagonistas de pan integrina com melhores propriedades farmacocinéticas
GB201916071D0 (en) * 2019-11-05 2019-12-18 Univ Bristol Treatment for nephrotic syndrome
EP4114429A2 (en) * 2020-03-06 2023-01-11 Allegro Pharmaceuticals, LLC Treatments for improving or lessening impairment of mitochondrial function
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
US20240000930A1 (en) 2020-12-09 2024-01-04 Siwa Corporation Methods and compositions for treating kidney diseases
JP7699774B2 (ja) * 2021-09-07 2025-06-30 公立大学法人名古屋市立大学 間質性膀胱炎・膀胱痛症候群の予防又は治療用医薬組成物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
BR9610422A (pt) 1995-08-30 1999-07-13 Searle & Co Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina
JP2000502704A (ja) 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
EP0895475A4 (en) 1995-12-29 2000-08-23 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
UA60311C2 (uk) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US6794358B1 (en) * 1997-03-28 2004-09-21 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
JP2002510328A (ja) 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
JP2001511452A (ja) 1997-08-04 2001-08-14 スミスクライン・ビーチャム・コーポレイション インテグリン受容体アンタゴニスト
ATE322508T1 (de) 1998-01-23 2006-04-15 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6- integrin und fibronectin in vitro zu hemmen
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
IT1299575B1 (it) 1998-07-23 2000-03-16 Demetrio Biancucci Suola per calzatura provvista di rampini o mezzi chiodati in grado di passare da una posizione a contatto con il suolo ad una posizione
EP0982036A1 (en) 1998-08-28 2000-03-01 Wilex Biotechnology GmbH Modulation of Beta2 -integrin-mediated cell adhesion
US6451972B1 (en) 1998-11-16 2002-09-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
SK11732001A3 (sk) 1999-02-20 2002-04-04 Merck Patent Gmbh Deriváty beta-alanínu
CA2366514C (en) * 1999-04-13 2009-09-15 Manfred Schmitt Diagnostic and therapeutic use of antibodies against the urokinase receptor
PT1187592E (pt) * 1999-06-02 2007-10-19 Merck & Co Inc Antagonistas dos receptores de integrina alfa v
AU7099900A (en) 1999-09-03 2001-04-10 Brigham And Women's Hospital Peptides that bind to urokinase receptor
EP1700606A1 (en) 1999-09-14 2006-09-13 Biogen Idec MA, Inc. Therapies for chronic renal failure using one or more integrin antagonists
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
DE10028575A1 (de) * 2000-06-14 2002-03-14 Basf Ag Integrinliganden
GB9928882D0 (en) * 1999-12-08 2000-02-02 Zeneca Ltd Assay method
US6825167B1 (en) * 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
GB0011817D0 (en) 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
AU2001268490A1 (en) 2000-06-15 2001-12-24 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
UY26780A1 (es) 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
US6649597B1 (en) * 2000-06-22 2003-11-18 The University Of Iowa Research Foundation Targeting vector to the urokinase plasminogen activator receptor
GB0016791D0 (en) * 2000-07-07 2000-08-30 Novartis Ag Organic compounds
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20020072518A1 (en) 2000-08-29 2002-06-13 Khanna Ish Kumar Bicyclic alphavbeta3 antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6720327B2 (en) 2000-09-27 2004-04-13 Pharmacia Corporation Lactone integrin antagonists
US20020072500A1 (en) 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
EP1197553A1 (en) 2000-10-12 2002-04-17 A3D GmbH, Antisense Design & Drug Development Antisense nucleic acid against alphaV integrin
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6794385B2 (en) 2001-08-08 2004-09-21 Pharmacia & Upjohn, S.P.A. Benzoxazine derivatives useful as integrin receptor antagonists
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
US7138230B2 (en) * 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
ITRM20020402A1 (it) 2002-07-29 2004-01-29 Sigma Tau Ind Farmaceuti Derivati fluoro-alchil-ciclopeptidi ad attivita' anti-integrine.
DK1539739T3 (da) * 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
MXPA05006732A (es) 2002-12-20 2005-09-08 Pharmacia Corp El isomero r de compuesto de beta-aminoacido como derivados de antagonistas de receptor de la integrina.
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
CN1747966A (zh) * 2003-02-06 2006-03-15 默克专利有限公司 肽磺酰胺
KR100568755B1 (ko) 2003-04-03 2006-04-07 주식회사 리젠 바이오텍 Yh 모티프를 포함하는 펩타이드를 유효성분으로함유하는 혈관신생 억제제
AU2004227414A1 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals iRNA conjugates
US7560244B2 (en) * 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
WO2005000871A2 (en) * 2003-06-23 2005-01-06 Centocor, Inc. Peptides antagonistic to an anti-angiogenic antibody and uses therefor
ITMI20031476A1 (it) 2003-07-18 2005-01-19 Univ Degli Studi Milano Composti peptido-mimetici a struttura azabicicloalcanica comprendenti la sequenza rgd
WO2005117936A2 (en) 2004-05-07 2005-12-15 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
CN101022830A (zh) 2004-05-25 2007-08-22 阿特努奥恩公司 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂( u P A)与其受体( u P A R)的复合物的配位体:在诊断或治疗中的识别和用途
EP1802618A1 (en) 2004-10-14 2007-07-04 Pharmacia Corporation Biphenyl integrin antagonists
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20070244046A1 (en) * 2006-03-29 2007-10-18 Margarita Gutova Identification and characterization of cancer stem cells and methods of use
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US20080020979A1 (en) * 2006-06-09 2008-01-24 Rapraeger Alan C Peptides of Syndecan-1 For Inhibiting Angiogenesis
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
US20100158858A1 (en) * 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
AU2008316793A1 (en) 2007-10-26 2009-04-30 Genentech, Inc. Inhibition of urokinase-type plasminogen activator (uPA) activity
ES2457822T3 (es) * 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
KR20200058590A (ko) * 2008-04-30 2020-05-27 이뮤노젠 아이엔씨 가교제 및 그 용도
CA2779958A1 (en) * 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
CN104768975A (zh) * 2012-08-31 2015-07-08 北卡罗来纳大学教堂山分校 用于增强或抑制胰岛素-样生长因子1(igf-1)的单克隆抗体

Similar Documents

Publication Publication Date Title
JP2011503065A5 (https=)
Ippolito et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit
JP2008543886A5 (https=)
JP2013518056A5 (https=)
JP2021511360A5 (https=)
JP2008523153A5 (https=)
JP2012533546A5 (https=)
JP2011528713A5 (https=)
JP2013500986A5 (https=)
RU2006105101A (ru) Арилокси и арилалкиленокси замещенные имидазохинолины
JP2010527373A5 (https=)
JP2013537423A5 (https=)
JP2018518537A5 (https=)
JP2015500843A5 (https=)
JP2009535352A5 (https=)
JP2008513504A5 (https=)
TR200201636T2 (tr) Sübstitüe edilmiş oksazolidinonlar ve bunların kullanımı
JP2011521911A5 (https=)
RU2009111113A (ru) Мидуляторы mglur5
JP2011246469A5 (https=)
JP2010521516A5 (https=)
JP2013544854A5 (https=)
JP2013506674A5 (https=)
CA2547347A1 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
JP2008503221A5 (https=)